Leadership

Dan Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on behalf of publicly traded companies, with deep experience in both oncology and strategic partnership generation. Prior to joining Cue Biopharma, Mr. Passeri served as President and Chief Executive Officer as well as Vice Chairman of the Board of Curis, Inc. Prior to joining Curis, he was employed by GeneLogic Inc., most recently as Senior Vice President, Corporate Development and Strategic Planning. Prior to his work at GeneLogic, Mr. Passeri served as Director of Technology Management at Boehringer Mannheim. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in Biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in Biology from Northeastern University.

Anish Suri is an immunologist with extensive experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, including a key leadership position overseeing strategic Immunoscience initiatives. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University in St Louis, Missouri.

Matteo Levisetti brings extensive experience leading global clinical development for mid and large-size pharmaceutical companies. Prior to joining Cue Biopharma, Matteo served as Chief Medical Officer at DNAtrix directing and managing clinical operations and regulatory strategy for several clinical trials. Matteo also served as Chief Medical Officer at Dauntless Pharmaceuticals where he was responsible for all aspects of clinical development of endocrinology and oncology assets. Previously, Matteo directed immuno-oncology programs as Executive Director of Clinical Development at Mirati Therapeutics. Before joining Mirati, Matteo served as Global Head & Vice President, Translational Medicine, Immunology and Inflammation at Roche Pharma Research & Early Development and held several senior positions with Pfizer, including Global Clinical Lead. While working with Pfizer, Matteo led multiple early clinical development programs across several therapeutic areas, including endocrinology, immunology and oncology. Earlier in his career, Matteo held joint appointments as Assistant Professor in the Departments of Medicine, Pathology, and Immunology at Washington University School of Medicine. Matteo received his MD from the University of Chicago Pritzker School of Medicine, completed residency training in internal medicine at the University of Chicago Hospitals, and completed subspecialty training in endocrinology and a research fellowship in immunology with Dr. Emil R. Unanue at Washington University School of Medicine, St. Louis, Missouri.